Haemonetics Executive and Leadership Team

James D'Arecca, the Chief Financial Officer at Haemonetics, directs the company's financial strategy and operations. Overseeing all fiscal activities, D'Arecca ensures robust financial planning, accurate reporting, and effective capital allocation to support Haemonetics' global growth initiatives. This leadership role involves managing investor relations, optimizing financial performance, and driving profitability across all business segments. By maintaining stringent financial controls and identifying strategic investment opportunities, James D'Arecca directly contributes to the company's mission of improving patient care and reducing healthcare costs. The Chief Financial Officer's purview extends to risk management and ensuring compliance with all financial regulations, safeguarding the company's assets and enhancing shareholder value. D'Arecca's financial acumen underpins the company's ability to innovate and expand its market reach.

Marcia Silvestro, the Group Chief Financial Officer at Haemonetics, provides strategic financial leadership across Haemonetics' global business units. Silvestro oversees financial planning, analysis, and reporting for key operational groups, ensuring alignment with corporate financial objectives and market demands. This role involves managing financial performance, identifying growth opportunities, and optimizing resource allocation to support the company's mission of improving patient care. Marcia Silvestro's expertise in financial management is crucial for driving profitability and ensuring the sustainable development of Haemonetics' innovative medical products. The Group Chief Financial Officer's responsibilities include fostering strong financial discipline, mitigating financial risks, and supporting strategic decision-making across diverse market segments. Silvestro's financial stewardship is integral to Haemonetics' commitment to quality and its global impact.

Frankie Chan, the Executive Vice President & Chief Operating Officer at Haemonetics, orchestrates the company's global operational execution. Chan directs the integration of manufacturing, supply chain, and service delivery to ensure seamless product availability and customer support worldwide. This critical role involves optimizing operational efficiency, driving process improvements, and scaling Haemonetics' infrastructure to meet increasing market demand. Frankie Chan's leadership ensures that the company's innovative medical products reach customers effectively, supporting patient care and cost reduction goals. The Chief Operating Officer's responsibilities include managing cross-functional teams, implementing best practices in operational management, and fostering a culture of continuous improvement. By enhancing operational capabilities, Chan directly supports Haemonetics' strategic objectives and its commitment to making a difference for patients globally.

Keiko Hattori, the President, Haemonetics (Japan), leads the company's strategic operations and market development within Japan. Hattori directs all business activities, ensuring the effective delivery of Haemonetics' innovative medical products and solutions to the Japanese healthcare market. This leadership role focuses on expanding market share, fostering strong customer relationships, and driving growth in alignment with global company objectives. Keiko Hattori's deep understanding of the regional healthcare landscape is critical for tailoring Haemonetics' offerings to meet local patient needs and regulatory requirements. The President of Haemonetics (Japan) oversees sales, marketing, and operational functions, ensuring seamless integration with the company's broader mission to improve patient care and reduce costs. Hattori's leadership is instrumental in reinforcing Haemonetics' commitment to quality and integrity in a key international market.

Gregory Olen, the Vice President, Chief Information Officer at Haemonetics, leads the company's technology strategy and digital transformation efforts. Olen directs the development and implementation of IT infrastructure, cybersecurity measures, and data management systems that support Haemonetics' global operations and innovation pipeline. This executive position involves ensuring the reliability and security of all information systems, enabling efficient data flow for research, development, and customer service. Gregory Olen's strategic vision for technology empowers the organization to enhance patient care solutions and reduce healthcare costs through advanced digital capabilities. The Chief Information Officer's oversight extends to leveraging technology for competitive advantage, driving operational efficiencies, and supporting the company's entrepreneurial culture. Olen's focus on robust IT solutions is fundamental to Haemonetics' ongoing success and its commitment to quality and integrity.

Sandra Jesse, the Executive VP & Chief Legal Officer at Haemonetics, directs the company's comprehensive legal strategy and compliance framework. Jesse oversees all legal affairs, including corporate governance, intellectual property, regulatory matters, and litigation, ensuring adherence to global legal standards. This senior leadership position is vital for safeguarding Haemonetics' interests and supporting its mission to enhance patient care and reduce healthcare costs. Sandra Jesse's legal expertise guides the company through complex regulatory landscapes and contractual obligations, fostering trust and integrity in all business dealings. The Chief Legal Officer's role involves advising executive leadership and the Board of Directors on legal implications of business decisions and strategic initiatives. Jesse's commitment to legal excellence underpins Haemonetics' reputation and its unwavering dedication to quality worldwide.